

Special Issue

The Employment of Biocompatible Nanomaterials for Disease Diagnosis and Treatment Based on Catalytic Reactions

Message from the Guest Editor

Recent advancements in nanochemistry have ushered in an array of novel nanocatalysts, including nanoenzymes, photocatalysts, and electrocatalysts. These have been utilized in vivo to initiate catalytic reactions and modulate the biological microenvironment for therapeutic benefits. With the swift progression of nanocatalysts in biomedical applications, a new paradigm, "nanocatalytic medicine," has emerged. This concept is defined as "the employment of biocompatible nanomaterials for disease diagnosis and treatment based on catalytic reactions." By introducing non-toxic or minimally toxic nanocatalysts into pathological areas, therapeutic chemical reactions are "catalyzed," fostering a more biocompatible and sustainable approach. In these catalyzed reactions, the reactants are typically the inherent biochemicals of the pathological region, as opposed to delivered therapeutic agents. "Nanocatalytic medicine" directs catalytic reactions to optimize therapeutic outcomes, effectively translating the catalytic efficiencies and selectivity that chemists have strived to achieve over the past century into high-performance therapeutic diagnostics with reduced side effects.

Guest Editor

Prof. Dr. Yi Wang

Center for Advanced Low-Dimension Materials, State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China

Deadline for manuscript submissions

closed (15 July 2025)



Catalysts

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 7.6



mdpi.com/si/224019

Catalysts
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
catalysts@mdpi.com

[mdpi.com/journal/
catalysts](https://mdpi.com/journal/catalysts)





Catalysts

an Open Access Journal
by MDPI

Impact Factor 4.0
CiteScore 7.6



[mdpi.com/journal/
catalysts](https://mdpi.com/journal/catalysts)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Keith Hohn

Carl R. Ice College of Engineering, Kansas State University, Manhattan,
KS, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), Inspec, Ei Compendex, CAPlus / SciFinder, CAB Abstracts, and other databases.

Journal Rank:

JCR - Q2 (Chemistry, Physical) / CiteScore - Q1 (General Environmental Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.6 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).